Who Paid My Doc
John Park
Reproductive Endocrinology Raleigh, NC Medical Doctor
NPI 1063578961 CMS profile 479337
2601 Lake Dr, Suite 301, Raleigh, NC 27607
General payments
$173,382
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$3,996,492
Through program year 2025, John Park of Raleigh, NC is reported in the CMS Open Payments database as having received $173,382 across 291 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,996,492 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $15,708 | 19 | |
| 2024 | General | $10,851 | 24 | |
| 2023 | General | $54,625 | 56 | |
| 2022 | General | $37,519 | 71 | |
| 2021 | General | $14,017 | 25 | |
| 2020 | General | $14,472 | 32 | |
| 2019 | General | $26,191 | 64 |
Beside peers
- John Park
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to John Park were reported at $15,708. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | John Park | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $26,191 | $196 | $77–$425 | $163 |
| 2020 | $14,472 | $81 | $35–$182 | $114 |
| 2021 | $14,017 | $102 | $43–$247 | $132 |
| 2022 | $37,519 | $139 | $62–$303 | $149 |
| 2023 | $54,625 | $141 | $65–$285 | $160 |
| 2024 | $10,851 | $144 | $65–$302 | $164 |
| 2025 | $15,708 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
291 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in North Carolina
Genevieve Neal-Perry
Reproductive Endocrinology · Raleigh, NC
Erika Johnston-MacAnanny
Reproductive Endocrinology · Winston Salem, NC
Bruce Lessey
Reproductive Endocrinology · Winston Salem, NC
Steven Young
Reproductive Endocrinology · Chapel Hill, NC
Jenna Hynes
Reproductive Endocrinology · Raleigh, NC
Edward McClellan
Reproductive Endocrinology · Fort Bragg, NC
Related records
Reproductive Endocrinology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.